Celcuity (NASDAQ:CELC) Shares Up 6.7% – Time to Buy?

Celcuity, Inc. (NASDAQ:CELC) was up 6.7% on Tuesday . The company traded as high as $115.84 and last traded at $115.8650. Approximately 716,307 shares were traded during trading, a decline of 30% from the average daily volume of 1,022,356 shares. The stock had previously closed at $108.58.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on CELC shares. Wells Fargo & Company dropped their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC restated a “buy” rating and set a $157.00 target price on shares of Celcuity in a research report on Friday, May 15th. Citizens Jmp raised their price target on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research report on Monday, May 4th. Craig Hallum cut their price objective on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Celcuity currently has a consensus rating of “Moderate Buy” and an average price target of $152.09.

Celcuity Stock Up 5.8%

The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The company has a market cap of $5.60 billion, a PE ratio of -29.47 and a beta of 0.16. The business’s 50 day moving average is $112.60 and its 200-day moving average is $110.75.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, analysts predict that Celcuity, Inc. will post -3.69 EPS for the current year.

Insider Buying and Selling

In related news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares of the company’s stock, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.33% of the company’s stock.

Institutional Investors Weigh In On Celcuity

A number of large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its stake in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the period. BNP Paribas Financial Markets grew its position in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares during the last quarter. Parallel Advisors LLC bought a new position in Celcuity in the first quarter worth about $38,000. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity during the 4th quarter valued at approximately $42,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.